

Supplementary data

Table 2. Characteristics, etiology of infections and outcomes among 631 patients receiving carbapenem treatment according to hospital group.

		Group I	Group II	Group III
	Patients	174	249	208
INFECTION	TYPE OF INFECTION			
	Community-acquired	64 (36.8)	110 (44.2)	119 (57.2)
	Nosocomial	78 (44.8)	78 (31.3)	54 (26.0)
	Healthcare associated	32 (18.4)	61 (24.5)	35 (16.8)
	FOCUS OF INFECTION			
	Urinary			78 (37.5)
	Intra-abdominal	44 (25.3)	89 (35.7)	55 (26.4)
	Respiratory	48 (27.6)	83 (33.3)	30 (14.4)
	Skin and soft tissue	41 (23.6)	44 (17.7)	32 (15.4)
	Unknown	22 (12.6)	22 (8.8)	3 (1.4)
	Febrile neutropenia	7 (4.0)	12 (4.8)	3 (1.4)
	Osteoarticular	7 (4.0)	4 (1.6)	3 (1.4)
	Others	4 (2.3)	0 (0.0)	3 (1.4)
		5 (2.9)	4 (1.6)	3 (1.4)
	Bacteremia			53 (25.5)
	Septic shock	27 (15.5)	56 (22.5)	30 (14.4)
		29 (16.7)	37 (14.9)	

	CULTURES			
	Positive	115	156	120
Microorganisms isolated*		35 (30.4)	70 (44.9)	57 (47.5)
	Escherichia coli	10 (8.7)	36 (23.1)	28 (23.3)
	• ESBL- producing <i>E.coli</i>	23 (20.0)	23 (14.7)	16 (13.3)
	Klebsiella pneumoniae	16 (13.9)	11 (7.1)	9 (7.5)
	• ESBL- producing <i>K. pneumoniae</i>	12 (10.4)	18 (11.5)	14 (11.7)
	<i>Pseudomonas aeruginosa</i>	1 (0.9)	1 (0.6)	0 (0.0)
	• <i>P. aeruginosa</i> MR	6 (5.2)	7 (4.5)	3 (2.5)
	<i>Enterococcus</i> spp.	5 (4.4)	4 (2.6)	3 (2.5)
	<i>Staphylococcus aureus</i>	1 (0.9)	2 (1.3)	3 (2.5)
	• MRSA	3 (2.6)	11 (7.1)	5 (4.2)
	<i>Enterobacter</i> spp.	3 (2.6)	3 (1.9)	4 (3.3)
	<i>Proteus</i> spp.	3 (2.6)	6 (3.9)	1 (0.8)
	<i>Streptococcus</i> spp.			
TREATMENT	Mean treatment duration, days ($\pm$ SD)	8.6 ($\pm$ 6.7)	8.2 ($\pm$ 5.3)	8.8 ($\pm$ 6.7)
	REASONS FOR EMPIRICAL TREATMENT**			
	Severity	44 (25.3)	42 (16.9)	36 (17.3)
	Suspicion of ESBL-bacteria	31 (17.8)	46 (18.5)	20 (9.6)
	Suspicion of polymicrobial mixed infection	30 (17.2)	49 (19.7)	53 (25.5)
	Rescue	21 (12.1)	32 (12.9)	41 (19.7)
	Suspicion of <i>Pseudomonas aeruginosa</i>	17 (9.8)	23 (9.2)	8 (3.9)
	Adherence to local protocols	5 (2.9)	10 (4.0)	3 (1.4)
	REASONS FOR DISCONTINUATION			

	De-escalation	72 (41.4)	87 (34.9)	71 (34.1)
	Completion of treatment	65 (37.4)	126 (50.6)	106 (51.0)
	Death	16 (9.2)	17 (6.8)	17 (8.2)
	Failure	13 (7.5)	13 (5.2)	6 (2.9)
	Adverse reactions	1 (0.6)	1 (0.4)	2 (1.0)

Data are given in n (%); *Percentages are referred to positive cultures; ** Multiple answers were allowed.

Group I, large university hospitals; Group II, medium-sized teaching hospitals; Group III, small hospitals.